Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Olivia Weaver"'
Publikováno v:
Emerging Trends in Drugs, Addictions, and Health, Vol 4, Iss , Pp 100159- (2024)
Objectives: Stimulants are a class of drugs approved for the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. However, they are also often used “off-label” as adjunct therapies for the treatment of obesity and depressi
Externí odkaz:
https://doaj.org/article/1b8d0fd779e649efa6f084ba0fe28e14
Purpose: Reducing initial exposure of “opioid naïve” patients to opioids is a public health priority. Identifying opioid naïve patients is difficult, as numerous definitions are used. The objective is to summarize current definitions and evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eefaeb7fa0a7f77b09d8c370c76a5934
https://doi.org/10.22541/au.167730125.53076426/v1
https://doi.org/10.22541/au.167730125.53076426/v1
Autor:
Katerina Maximova, Mahua Ghosh, Donna F. Vine, Spencer D. Proctor, Ethan Proctor, Olivia Weaver
Publikováno v:
Journal of the Endocrine Society
Context Women with polycystic ovary syndrome (PCOS) have increased incidence of atherogenic dyslipidemia and cardiovascular disease (CVD). Interventions targeting atherogenic dyslipidemia to reduce CVD risk are limited in women with PCOS. Objective T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a33e59c3647c07cef52eb7436102fbaf
http://europepmc.org/articles/PMC8282216
http://europepmc.org/articles/PMC8282216
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee1f54476b4d185631ddf1a5f5359a65
https://doi.org/10.1530/endoabs.70.aep402
https://doi.org/10.1530/endoabs.70.aep402
Autor:
Donna F. Vine, Ethan Proctor, Mahua Ghosh, Olivia Weaver, Spencer D. Proctor, Katerina Maximova
Publikováno v:
Journal of the Endocrine Society
Background: Polycystic ovary syndrome (PCOS) is highly associated with the metabolic syndrome (MetS): obesity, insulin resistance and atherogenic dyslipidemia. Women with PCOS-MetS are at higher risk of developing ischemic cardiovascular disease (CVD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc5bcbfa6d643ba83c5982f53ffcfd8c
http://europepmc.org/articles/PMC7208267
http://europepmc.org/articles/PMC7208267